Laurus Labs Q1 FY27 results show record quarterly revenue of ₹2,026 crore, up 29% year-on-year (YoY). EBITDA rose 66% YoY to ₹644 crore, with margins expanding to 31.8%.
In this article, you’ll find a complete breakdown of Laurus Labs’ Q1 FY27 performance, including divisional revenue, R&D investments, and leadership commentary.
Financial Summary at a Glance
Laurus Labs Ltd. announced its Q1 FY27 results on 24 July 2026. As a result, the company reported strong growth across nearly every key financial metric.
| Metric (₹ Crore) | 1Q FY27 | 1Q FY26 | YoY Growth |
|---|---|---|---|
| Revenue | 2,026 | 1,570 | 29% |
| Gross Margins | 62.7% | 59.4% | +3.3 pts |
| EBITDA | 644 | 389 | 66% |
| EBITDA Margins | 31.8% | 24.8% | +7.0 pts |
| PBT | 481 | 224 | 115% |
| Net Profit | 368 | 163 | 126% |
| EPS (Diluted) | 6.8 | 3.0 | 127% |
Therefore, both profitability and margin expansion outpaced revenue growth this quarter, signaling improved operational efficiency.
What Leadership Said
Dr. Satyanarayana Chava, Founder & CEO of Laurus Labs, described the quarter as a record performance backed by expanding profitability and continued portfolio transformation. He credited growing commercial deliveries within CDMO and steady strength in the Affordable Medicines portfolio for the results.
Additionally, Dr. Chava highlighted two key milestones: an agreement to in-license two Antibody Drug Conjugates (ADCs), and the final handover of a new land parcel supporting long-term growth plans.
Meanwhile, V V Ravi Kumar, Executive Director & CFO, noted that the company delivered strong operating performance despite macroeconomic volatility. He pointed to improved capacity utilization and operating leverage as key drivers behind the EBITDA margin gains, along with a favorable segment mix supporting gross margin expansion.
Divisional Revenue Performance
Laurus Labs operates across two core business segments: CDMO and Affordable Medicines (Generics). Both divisions contributed to this quarter’s growth.
| Segment (₹ Crore) | 1Q FY27 | 1Q FY26 | YoY Growth |
|---|---|---|---|
| CDMO | 870 | 522 | 67% |
| — Small Molecules | 835 | 493 | 69% |
| — Bio | 35 | 29 | 21% |
| Affordable Medicines | 1,156 | 1,048 | 10% |
| — API | 654 | 637 | 3% |
| — FDF | 502 | 411 | 22% |
| Total Revenue | 2,026 | 1,570 | 29% |
Notably, CDMO revenue grew significantly faster than Affordable Medicines this quarter, driven largely by commercial project ramp-ups.
CDMO – Small Molecules Highlights
The CDMO Small Molecules business reported revenue of ₹835 crore, up 69% YoY. This growth came mainly from late-stage clinical and commercial API supplies, along with the ramp-up of new growth projects.
Key developments in this segment include:
- Continued focus on new modalities with key partners
- Advancing commercial peptides manufacturing based on customer demand
- A healthy pipeline of over 125 active projects across Human health, Animal health, and Crop science
- Ongoing CAPEX investment in large-scale API and fermentation capacity in Vizag
Bio – Large Molecules Highlights
The Bio division reported revenue of ₹35 crore, up 21% YoY. In particular, the company saw strong traction in enzymatic technology applications across small molecule clinical and commercial API projects.
Furthermore, Laurus Labs expects its new fermentation facility to be commissioned by Q3 FY27.
Affordable Medicines (Generics) Highlights
The Affordable Medicines division posted revenue of ₹1,156 crore, up 10% YoY. Growth came from steady ARV demand, established product volume growth, and new product launches in the US.
Additional highlights from this segment:
- Maintained consistent delivery performance despite ongoing global supply chain challenges
- Capacity expansion and resource allocation remain on track, with a focus on integrated CMO supplies
- The KRKA JV’s FDF site progress remains on track, with Phase-I production blocks expected to open in mid-2027
In terms of regulatory filings, Laurus Labs has cumulatively filed 92 DMFs to date. The company also filed 2 new product dossiers in developed markets during Q1 FY27, bringing its cumulative developed-market FDF filings to 96.
R&D Investment and Innovation
Laurus Labs’ total R&D investment, including capital R&D expenditure, reached ₹118 crore this quarter — equivalent to 5.8% of revenue. This marks a 74% YoY increase, driven by development efforts in Advanced Biologics infrastructure, including Gene Therapy and Antibody Drug Conjugates.
Consequently, the company also in-licensed two ADC assets from Aarvik Therapeutics for development and commercialization in India.
Quality and ESG Highlights
Laurus Labs completed 24 quality audits during the quarter, passing all inspections without critical findings. In addition, the Science Based Targets initiative (SBTi) approved the company’s near-term, science-based emissions reduction targets — an important milestone in its sustainability journey.
About Laurus Labs
Laurus Labs is a research-driven pharmaceutical and biotechnology company focused on APIs and Finished Dosage Forms across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. The company employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators such as the USFDA, WHO, and EMA.
In FY2026, Laurus Labs generated ₹6,813 crore in revenue and holds a “BBB” MSCI ESG rating, reflecting its focus on transparency and ethical business practices.
Conclusion
Laurus Labs Q1 FY27 results reflect strong, broad-based growth across CDMO, Affordable Medicines, and R&D investment. With record revenue, expanding margins, and continued innovation in biologics, the company has reinforced its position as a leading research-driven pharmaceutical player in India.
As Laurus Labs continues its CAPEX programs and portfolio transformation, this quarter’s performance signals sustained momentum heading into FY27 and beyond.
Want more updates on Laurus Labs’ quarterly performance? Visit the company’s investor relations page for the full earnings call transcript and future updates.
